PMC:7443692 / 7740-8029 JSONTXT

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T35","span":{"begin":95,"end":105},"obj":"Species"}],"attributes":[{"id":"A35","pred":"ncbi_taxonomy_id","subj":"T35","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"The proposed use of soluble extracellular domains of ACE2 as decoy, competitive inhibitors for SARS-CoV-2 infection emphasizes the critical need for understanding the glycosylation profile of ACE2 so that optimally active biologics can be produced (Lei et al., 2020; Monteil et al., 2020)."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T40","span":{"begin":0,"end":289},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The proposed use of soluble extracellular domains of ACE2 as decoy, competitive inhibitors for SARS-CoV-2 infection emphasizes the critical need for understanding the glycosylation profile of ACE2 so that optimally active biologics can be produced (Lei et al., 2020; Monteil et al., 2020)."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T26","span":{"begin":95,"end":105},"obj":"Disease"},{"id":"T27","span":{"begin":106,"end":115},"obj":"Disease"}],"attributes":[{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"The proposed use of soluble extracellular domains of ACE2 as decoy, competitive inhibitors for SARS-CoV-2 infection emphasizes the critical need for understanding the glycosylation profile of ACE2 so that optimally active biologics can be produced (Lei et al., 2020; Monteil et al., 2020)."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T908","span":{"begin":53,"end":57},"obj":"Protein"},{"id":"T909","span":{"begin":192,"end":196},"obj":"Protein"}],"attributes":[{"id":"A908","pred":"uniprot_id","subj":"T908","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"},{"id":"A909","pred":"uniprot_id","subj":"T909","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"}],"text":"The proposed use of soluble extracellular domains of ACE2 as decoy, competitive inhibitors for SARS-CoV-2 infection emphasizes the critical need for understanding the glycosylation profile of ACE2 so that optimally active biologics can be produced (Lei et al., 2020; Monteil et al., 2020)."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T39","span":{"begin":106,"end":115},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"}],"text":"The proposed use of soluble extracellular domains of ACE2 as decoy, competitive inhibitors for SARS-CoV-2 infection emphasizes the critical need for understanding the glycosylation profile of ACE2 so that optimally active biologics can be produced (Lei et al., 2020; Monteil et al., 2020)."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T29","span":{"begin":167,"end":180},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"The proposed use of soluble extracellular domains of ACE2 as decoy, competitive inhibitors for SARS-CoV-2 infection emphasizes the critical need for understanding the glycosylation profile of ACE2 so that optimally active biologics can be produced (Lei et al., 2020; Monteil et al., 2020)."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T27","span":{"begin":167,"end":180},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"The proposed use of soluble extracellular domains of ACE2 as decoy, competitive inhibitors for SARS-CoV-2 infection emphasizes the critical need for understanding the glycosylation profile of ACE2 so that optimally active biologics can be produced (Lei et al., 2020; Monteil et al., 2020)."}

{"project":"2_test","denotations":[{"id":"32841605-32332765-19659500","span":{"begin":261,"end":265},"obj":"32332765"},{"id":"32841605-32333836-19659501","span":{"begin":283,"end":287},"obj":"32333836"}],"text":"The proposed use of soluble extracellular domains of ACE2 as decoy, competitive inhibitors for SARS-CoV-2 infection emphasizes the critical need for understanding the glycosylation profile of ACE2 so that optimally active biologics can be produced (Lei et al., 2020; Monteil et al., 2020)."}